for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Amgen, Inc.

AMGN.OQ

Latest Trade

207.84USD

Change

1.06(+0.51%)

Volume

2,169,489

Today's Range

206.36

 - 

208.50

52 Week Range

200.50

 - 

276.69

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
206.78
Open
208.32
Volume
2,169,489
3M AVG Volume
54.16
Today's High
208.50
Today's Low
206.36
52 Week High
276.69
52 Week Low
200.50
Shares Out (MIL)
567.85
Market Cap (MIL)
117,420.50
Forward P/E
12.59
Dividend (Yield %)
3.40

Next Event

Q3 2021 Amgen Inc Earnings Release

Latest Developments

More

Amgen Says Neumora Got Rights To Develop, Commercialize Amgen Programs Targeting Casein Kinase 1 Delta & Glucocerebrosidase For Neurodegenerative Diseases

Amgen Announces New Positive Phase 3 Data For Repatha In ACS Patients

Amgen Inc Reports QTRLY Earnings Per Share of $0.81

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Amgen, Inc.

Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.

Industry

Biotechnology & Drugs

Contact Info

1 Amgen Center Dr

THOUSAND OAKS, CA

91320-1730

United States

+1.805.4471000

http://www.amgen.com/

Executive Leadership

Robert A. Bradway

Chairman of the Board, President, Chief Executive Officer

Peter H. Griffith

Chief Financial Officer, Executive Vice President

Jonathan P. Graham

Executive Vice President, General Counsel, Secretary

Lori A. Johnston

Executive Vice President - Human Resources

Murdo Gordon

Executive Vice President - Global Commercial Operations

Key Stats

2.56 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

23.7K

2019

23.7K

2020

25.4K

2021(E)

26.0K
EPS (USD)

2018

14.400

2019

14.820

2020

16.600

2021(E)

16.422
Price To Earnings (TTM)
21.02
Price To Sales (TTM)
4.61
Price To Book (MRQ)
14.28
Price To Cash Flow (TTM)
12.74
Total Debt To Equity (MRQ)
397.50
LT Debt To Equity (MRQ)
345.07
Return on Investment (TTM)
11.53
Return on Equity (TTM)
9.21

Latest News

Latest News

Amgen to invest $100 million in SoftBank-backed Neumora

U.S. biotech Amgen Inc has made a $100-million equity investment in Neumora Therapeutics, the brain disease drug developer said on Thursday, adding that it will also get global rights to develop and sell certain of Amgen's experimental drugs for neurodegenerative diseases.

Amgen blocks Sandoz, Zydus generics of psoriasis drug Otezla until 2028

Amgen has won a ruling in New Jersey federal court that blocks Sandoz Inc and Zydus Pharmaceuticals' proposed generics of its blockbuster psoriasis drug Otezla until 2028, the company said.

Lung cancer patients in England to receive Amgen drug that targets a gene mutation

Lung cancer patients in England will become the first in Europe to receive a drug made by U.S. biotech Amgen Inc that targets a specific gene mutation, the country's health service said on Friday.

Amgen says it expects pandemic to limit sales through 2021

U.S. biotech Amgen Inc on Tuesday said its second-quarter revenue rose 5%, but recovery from the COVID-19 pandemic, which has limited patient interactions with healthcare providers, is expected to hit sales for the rest of 2021.

Amgen says it expects pandemic to limit sales through 2021

U.S. biotech Amgen Inc on Tuesday said its second-quarter revenue rose 5%, but recovery from the COVID-19 pandemic, which has limited patient interactions with healthcare providers, is expected to remain gradual for the rest of 2021.

AstraZeneca-Amgen drug gets FDA speedy review as asthma treatment

Drugmakers AstraZeneca and Amgen said on Thursday their experimental drug tezepelumab was granted a speedy review by the U.S. Food and Drug Administration for potential approval as a treatment for asthma.

AstraZeneca-Amgen drug gets FDA's speedy review for asthma

Drugmaker AstraZeneca said on Thursday its experimental drug tezepelumab was granted a speedy review by the U.S. Food and Drug Administration for potential approval as a treatment for asthma, with action expected in the first quarter next year.

Bayer sues Dr. Reddy's over planned generic of cancer drug Nexavar

Bayer Healthcare LLC and Amgen subsidiary Onyx Pharmaceuticals Inc jointly sued India-based drugmaker Dr. Reddy's Laboratories Inc on Wednesday over its proposed generic version of their cancer drug Nexavar.

FDA approves Amgen drug for lung cancer with specific mutation

The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for lung cancer patients with a specific mutation in a gene known as KRAS whose disease has worsened after treatment with chemotherapy or other medicines.

FDA approves Amgen drug for lung cancer with specific mutation

The U.S. Food and Drug Administration on Friday approved an Amgen Inc drug for non-small cell lung cancer with a specific mutation in a gene known as KRAS in patients whose disease has worsened after treatment with chemotherapy or other medicines.

U.S. Supreme Court snubs Novartis appeal over arthritis drug Enbrel

The U.S. Supreme Court on Monday dashed Novartis AG's hopes of launching a generic version of Amgen Inc's multibillion-dollar rheumatoid arthritis Enbrel, declining to hear the company's challenge to two patents on the drug.

IN BRIEF: Amgen sues Aurobindo over proposed generic for dialysis patients

Amgen Inc sued generic drugmaker Aurobindo Pharma Ltd in Delaware federal court, alleging in a complaint entered Friday that Aurobindo's planned generic of its drug Parsabiv to treat a parathyroid condition in dialysis patients will infringe its patents.

US STOCKS-Dow, Nasdaq weighed down by Microsoft, Amgen; all eyes on Fed

* Dow down 0.35%, S&P flat, Nasdaq off 0.23% (Updates prices to early afternoon)

Amgen profit, sales fall on lower drug prices; shares drop 3.4%

U.S. biotech Amgen Inc on Tuesday said its first-quarter sales and profit fell due to a 7% drop in its net drug prices and the COVID-19 pandemic, which continued to limit patient interactions with healthcare providers.

Amgen 1st-quarter profit, sales fall; lower drug prices cited

U.S. biotech Amgen Inc on Tuesday said its first-quarter sales and profit fell due to a 7% drop in its net drug prices and the COVID-19 pandemic, which continued to limit patient interactions with healthcare providers.

Amgen bets on $1.9-billion Five Prime deal to grow in Asia-Pacific oncology market

Drugmaker Amgen Inc is buying Five Prime Therapeutics for about $1.9 billion to expand its line of gastric cancer drug candidates and its presence in Asia-Pacific, the companies said on Thursday.

AstraZeneca-Amgen drug could widen treatment options for severe asthma

AstraZeneca and Amgen's experimental drug reduced asthma attacks in patients with severe and uncontrolled forms of the respiratory condition in a large study, showing promise for wider use against different triggers.

Amgen loses bid to revive patents for cholesterol drug Repatha

A federal appeals court has rejected a bid by Amgen Inc to revive patents on its cholesterol drug Repatha after they were ruled invalid by a district court, a victory for Regeneron Pharmaceuticals Inc and Sanofi SA, which sell a rival drug.

Amgen issues 2021 outlook below Street view, shares dip

U.S. biotech Amgen Inc on Tuesday provided a 2021 earnings forecast below Wall Street estimates and said it had paused or halted enrollment for clinical trials of three cancer drugs.

Amgen 4th-quarter profit rises, 2021 outlook below Street view

Amgen Inc on Tuesday reported a higher-than-expected quarterly profit as sales of newer drugs offset lower revenue from older off-patent medications, but the biotech company forecast 2021 earnings below Wall Street estimates.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up